Flag of the European Union EU Clinical Trials Register Help

Clinical trials for ���������������������App .l

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43691   clinical trials with a EudraCT protocol, of which   7246   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: ���������������������App .l. Displaying page 1 of 1.
    EudraCT Number: 2020-000476-38 Sponsor Protocol Number: NN1436-4481 Start Date*: 2021-03-01
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effectiveness and safety of once weekly insulin icodec used with DoseGuide versus once daily basal insulin analogues in an insulin naïve type 2 diabetes population in a clinical practice setting
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) GR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-005492-12 Sponsor Protocol Number: BDTX-189-01 Start Date*: 2021-05-27
    Sponsor Name:Black Diamond Therapeutics, Inc.
    Full Title: MasterKey-01: A Phase 1/2, Open-label, Two-part, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutation...
    Medical condition: NSCLC, breast cancer, biliary tract cancer, or cervical cancer, any other solid tumors with specific gene mutations
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) NL (Prematurely Ended) ES (Completed) IT (Prematurely Ended) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006038-37 Sponsor Protocol Number: TAK-573-1501 Start Date*: 2022-10-11
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refr...
    Medical condition: Relapsed/Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Ongoing) DE (Ongoing) FR (Ongoing) IE (Ongoing) ES (Ongoing) GR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001492-16 Sponsor Protocol Number: M21NDN Start Date*: 2021-06-16
    Sponsor Name:NKI-AVL
    Full Title: Multicenter phase 3 trial comparing NeoADjuvant Ipilimumab + Nivolumab versus standard Adjuvant nivolumab in macroscopic stage III melanoma – NADINA
    Medical condition: Patients with stage III melanoma
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) PL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004231-25 Sponsor Protocol Number: MS201923_0050 Start Date*: 2021-05-11
    Sponsor Name:MERCK HEALTHCARE KGaA
    Full Title: A Phase II, open-label, single-arm study of berzosertib (M6620) in combination with topotecan in participants with relapsed platinumresistant small-cell lung cancer
    Medical condition: Relapsed platinum resistant small-cell lung cancer (SCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) ES (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2009-016622-13 Sponsor Protocol Number: CA187-016 Start Date*: 2010-06-23
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole with Lapatinib + Letrozole in Recurrent or Metastatic Breast Cancer Patients Who Are Hormone Receptor Pos...
    Medical condition: Locally recurrent or metastatic hormone receptor positive (HR+) breast cancer and either: • HER2+ disease with progression while on adjuvant antiendocrine therapy or at any time after adjuvant anti...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-001545-13 Sponsor Protocol Number: 54767414MMY3019 Start Date*: 2019-01-23
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Multiple Myeloma ...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) CZ (Ongoing) DE (Ongoing) NL (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000860-40 Sponsor Protocol Number: CC-220-MM-001 Start Date*: 2016-08-24
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 1B/2A Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in ...
    Medical condition: RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10067095 Multiple myeloma progression LLT
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) NL (Ongoing) DE (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2023 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA